Logotype for ProQR Therapeutics N.V.

ProQR Therapeutics (PRQR) investor relations material

ProQR Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ProQR Therapeutics N.V.
Evercore ISI 8th Annual HealthCONx Conference summary4 Dec, 2025

Company overview and technology

  • Focuses on RNA editing medicines to treat genetic and common diseases by modifying messenger RNA, enabling the creation or correction of proteins for health benefits.

  • Holds foundational IP for its RNA editing technology, developed over the past decade.

  • Entered a $4 billion partnership with Eli Lilly in 2021, covering up to 15 targets, with $125 million upfront and potential for $250 million per target in milestones plus royalties.

  • Maintains a wholly owned pipeline targeting liver and CNS diseases, including rare and common indications.

Lead program: AX-0810 for cholestatic diseases

  • AX-0810 targets NTCP to modulate bile acid uptake, aiming to treat PSC and BA, both with high unmet medical need.

  • Initial trial in healthy volunteers (33 subjects, 3 cohorts) is randomized, placebo-controlled, and double-blinded, with dosing over five weeks and 12-week follow-up.

  • Primary endpoints include serum bile acid concentration, bile acid ratios, and response to TUDCA challenge.

  • Initial safety and PK data expected by year-end; full PD and biomarker data in the first half of next year.

  • Phase 1B in PSC patients planned for the second half of next year, with results before year-end.

Clinical development strategy and regulatory pathway

  • Indication selection between PSC and BA for phase 2 will be finalized alongside phase 1 results, considering recruitment feasibility and disease characteristics.

  • Accelerated approval is possible due to high unmet need and lack of disease-modifying therapies; biomarker and imaging data may support this path.

  • Success in the healthy volunteer study defined as at least a twofold increase in serum bile acid, favorable bile acid ratio shift, and improved TUDCA clearance.

  • Editing percentage correlates linearly with bile acid increase; 5% editing yields twofold, 10% yields fourfold increase.

  • No safety concerns anticipated from increased editing or bile acid levels, supported by human genetics and prior clinical data.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next ProQR Therapeutics earnings date

Logotype for ProQR Therapeutics N.V.
Q4 202513 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next ProQR Therapeutics earnings date

Logotype for ProQR Therapeutics N.V.
Q4 202513 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

ProQR Therapeutics N.V. is a biotechnology company focused on developing innovative RNA therapies for genetic diseases. Established in 2012 in Leiden, Netherlands, ProQR pioneers RNA editing technologies, specifically its proprietary platform called Axiomer. This technology enables precise RNA editing by using a cell's own ADAR enzymes to alter specific nucleotides in RNA molecules, potentially reversing mutations or modulating protein expression to address unmet medical needs in various diseases. The company's approach to drug development is particularly significant for conditions that currently lack effective treatments. Over the years, ProQR has expanded its pipeline beyond its initial focus on cystic fibrosis to include a range of rare and common diseases, with ongoing research and development efforts in fields such as inherited retinal diseases and liver diseases. The company is headquartered in Leiden, Netherlands, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage